ATLANTA, GA – – (Globe Newswire – May 16, 2025) – – A shareholder class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about Iovance’s business, operations, and prospects, including allegations that: (1) new Authorized Treatment Centers (“ATCs”) were experiencing longer timelines to begin treating patients with Amtagvi; (2) Iovance’s sales team and new ATCs were ineffective in patient identification and patient selection for Amtagvi, leading to higher patient drop-offs; and (3) the foregoing dynamics led to higher costs and lower revenue because ATCs could not keep pace with manufactured product.

If you purchased shares of Iovance between May 9, 2024 and May 8, 2025, and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/iovance-biotherapeutics/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is July 14, 2025.